- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04343703
Suicide Prevention and Intervention in Spain: the SURVIVE Study (SURVIVE)
Suicide Prevention and Intervention (SURVIVE): Cohort Study and Nested Randomized Controlled Trials of Secondary Prevention Programs for Suicide Attempts
Study Overview
Status
Conditions
Detailed Description
Suicide is the leading cause of avoidable death worldwide, demanding urgent attention. Collecting national-representative data is the first step towards developing effective evidence-based public-policies.
The SURVIVE study presents four inter-connected objectives:
- To determine the incidence of suicide attempts in Spain
- To follow up suicide attempters with the aim of studying the probability of them re-attempting
- To identify influential risk factors to explain suicide attempts and an increased risk of re-attempting
- To determine the efficacy of secondary prevention programs to prevent suicide re-attempts in comparison to treatment as usual (TAU).
Study design: Multi-site-coordinated cohort study with nested randomized controlled trials. Participants will be recruited at mental-health sites distributed across Spain.
Participants: A cohort of 2.000 individuals presenting a suicide attempt will be established.
Individuals would be followed for 1-year, and assessed every 3 months.
Participants (age >18) that meet inclusion/exclusion criteria will be randomly allocated to:
1) telephone-based management, or 2) iFightDepression for Suicide (iFD-Survive), a web-based-self-management tool. These interventions will be tested against TAU.
Participants (age between 12-17) that meet inclusion/exclusion criteria will be randomly allocated to: 1)a face-to-face individual intervention designed for youths Specific Aware of Mental Health Intervention for adolescents (SAM) or 2) TAU.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Víctor Pérez, PhD
- Phone Number: 933160784
- Email: vperezsola@parcdesalutmar.cat
Study Contact Backup
- Name: Matilde Elices, PhD
- Phone Number: 933160784
- Email: melices@imim.es
Study Locations
-
-
-
Madrid, Spain, 28040
- Hospital Clinico San Carlos
-
Contact:
- Marina Diaz-Marsá
- Email: marinadiaz.marsa@salud.madrid.org
-
Madrid, Spain, 28046
- Hospital Universitario La Paz
-
Contact:
- Beatriz Rodriguez-Vega, PhD
-
-
Andalusia
-
Sevilla, Andalusia, Spain, 41013
- Hospital Universitario Virgen Del Rocio
-
Contact:
- Miguel Ruiz-Vegilla, PhD
- Email: mruizveguilla@yahoo.com
-
-
Asturias
-
Oviedo, Asturias, Spain, 33011
- Hospital Universitario Central de Asturias
-
-
Basque Country
-
Vitoria, Basque Country, Spain, 01004
- Hospital Santiago de Áraba
-
Contact:
- Itxaso Gonzalez Ortega, PhD
- Email: ITXASO.GONZALEZORTEGA@osakidetza.eus
-
Principal Investigator:
- María Purificación López-Peña, PhD
-
-
Catalonia
-
Badalona, Catalonia, Spain, 08916
- Hospital Germans Trias i Pujol
-
Contact:
- Manuel Canal-Rivero, PhD
- Email: mcanalri.germanstrias@gencat.cat
-
Barcelona, Catalonia, Spain, 08025
- Hospital de la Santa Creu i Sant Pau
-
Contact:
- Dolors Puigdemont, MD
- Email: mpuigdemont@santpau.cat
-
Barcelona, Catalonia, Spain, 08036
- Hospital Clinic
-
Contact:
- Iria Grande, PhD
- Email: igrande@clinic.cat
-
Barcelona, Catalonia, Spain, 08003
- Institute of Neuropsychiatry and Addictions, INAD, Parc de Salut Mar
-
Contact:
- Víctor Pérez, PhD
- Phone Number: 933160784
- Email: vperezsola@parcdesalutmar.cat
-
Contact:
- Matilde Elices, PhD
- Phone Number: 933160784
- Email: melices@imim.es
-
Sabadell, Catalonia, Spain, 08208
- Corporacio Sanitaria Parc Tauli
-
Contact:
- Clara López-Sola, PhD
- Email: clopezs@tauli.cat
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
General Inclusion Criteria:
- Female and males, age >= 12 years
- Having attended a hospital emergency department due to a suicide attempt
- Willing and able to comply with study procedures and to give written informed consent
Specific inclusion criteria for iFD-S:
- Minimum knowledge of internet use and availability of an internet device (tablet, computer, smartphone)
- Depressive symptoms according to PHQ-9 scores above 5
Specific inclusion criteria for SAM:
- Age between 12-17
- Informed consent of legal guardians
General Exclusion Criteria:
- Incapacity to give informed consent
- Lack of fluency in Spanish
- Currently taking part in another clinical study which, in the opinion of the investigator, is likely to interfere with the objectives of the SURVIVE study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Telephone-based management
Telephone-based management will consist of a three-phase intervention: 1) An initial 15-20 min call at 1 week of enrollment in which the cases manager introduces him/herself, and does a short assessment of the current suicide risk, 2) A 5-10 min telephone follow-up at 1, 3, 6, 9 and 12 months, 3) If suicide risk is detected, a 15-45 min crisis intervention call will be done, tailored to the participant's characteristics and context.
If deemed necessary, an emergency face-to-face appointment will be scheduled.
At each phone call information regarding the current treatment, adherence to mental health services, and current life stressors will be collected.
|
Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy.
For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.
Other Names:
|
EXPERIMENTAL: iFightDepression for Suicide
The iFightDepression-Survive (iFD-S) program is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD).
The iFD is intended to address mild-to-moderate depressive symptoms.
The iFD tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits.
The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets.
All of these aims to consolidate learning and promote self-monitoring.
For this study, an additional module (iFD-S) will be developed.
To that end, the expertise of a panel of mental health experts in suicide and cognitive-behavioral interventions will be asked.
The iFD-S also provides telephone guidance (2h per participant) during the use of the program.
|
Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy.
For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.
Other Names:
|
ACTIVE_COMPARATOR: Treatment as Usual
Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy.
For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.
TaU will consist of any routine procedures applied at each participating site.
|
The intervention consists of a series of phone calls aimed at providing follow up care of individuals at risk.
At each phone call the case manager collects information regarding the current treatment, adherence to mental health services, and current life stressors.
The iFD-Survive is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD).
The iFD is intended to address mild-to-moderate depressive symptoms.
The iDF tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits.
The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets.
All of these aims to consolidate learning and promote self-monitoring.
For this study, an additional module (iFD-S) will be developed.
The iFD-S also provides telephone guidance (2h per participant).
Other Names:
|
EXPERIMENTAL: Self Awareness of Mental Health
The Self Awareness of Mental Health (SAM) is an adaptation of the Youth Awareness of Mental Health program, originally developed for the Saving and Empowering Young Lives in Europe (SEYLE) study.
The SAM aims to raise mental health awareness about risk and protective factors associated with suicide, provide knowledge about depression and anxiety, and enhance the skills needed to cope with adverse life events and suicidal behavior.
The intervention is delivered by trained clinical psychologists in five, 45-60 minutes, face-to-face sessions.
|
Treatment as Usual (TaU) will vary across sites, however it generally implies a combination of case management strategies (including telephone calls, visits by mental health services) and pharmacotherapy.
For this study, any nonspecific intervention to address suicidal behavior or to prevent suicide will be considered as treatment as usual.
Other Names:
The SAM consist of five, face-to-face, individual sessions designed to raise awareness about depression, anxiety and suicidal behaviors as well as to enhancing skills to effectively cope with stressful life events and mood.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Suicide repetition (or death by suicide)
Time Frame: 12 months
|
The primary outcome is subsequent suicide attempts (and/or suicide mortality) captured across assessment points.
Is a binary variable (yes/no).
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brief Symptoms Inventory
Time Frame: 1 month
|
The BSI is a 53-item self-report scale designed to evaluate psychopathological and psychological symptoms, measuring nine dimensions (i.e.,somatization, obsession-compulsion, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation, and psychoticism) that can be summed up to reflect three global indices.
These synthetic indices are the General Severity Index (GSI), the Positive Symptom Distress Index, and the Positive Symptom Total.
In more detail, the BSI uses a 5-point Likert scale, ranging from 0 ("not at all") to 4 ("extremely").
Scores range from 0 to 212, higher scores mean a worse outcome.
|
1 month
|
Patient Health Questionnaire 9-items
Time Frame: 2 weeks
|
The PHQ-9 measures depressive symptoms in a scale from 0 (not at all) to 3 (nearly every day).
Scores range from 0 to 27 and higher scores mean a worse outcome.
The PHQ-9 A will be used for participants aged 12-17.
|
2 weeks
|
Generalized Anxiety Disorder 7-items
Time Frame: 2 weeks
|
GAD-7 consists of seven items measuring worry and anxiety symptoms.
Each item is scored on a four-point Likert scale (0-3) with total scores ranging from 0 to 21 with higher scores reflecting greater anxiety severity.
|
2 weeks
|
EuroQol 5D
Time Frame: 1 day
|
Part one provides a self-reported description of health problems into five dimensions.
Patients have to rate the severity of each dimension in a 5-point scale.
For part one, higher scores represent a worse outcome (less quality of life).Part two consist of a Visual Analogue Scale corresponding to the current state of the subject's health.
The lowest extreme (0) corresponds to the worst imaginable state, and the highest extreme (100) represents the best imaginable health state.
|
1 day
|
Barrat Impulsivity Scale
Time Frame: 2 weeks
|
The BIS is a 30-item widely used questionnaire that measures three aspects of impulsivity: 1) motor impulsiveness (acting without forethought), 2) attentional impulsiveness (tendency to make quick, non-reflexive decisions), and 3) non-planned impulsiveness (failure to prepare for future events).
Each item is rated in a 4 point scale (0-4).
Total scores range from 0 to 44, higher scores represent higher impulsivity.
|
2 weeks
|
Acquired capability of suicide Scale -Fearlesness about Death
Time Frame: 2 weeks
|
Acquired Capability for Suicide Scale-Fearlessness about Death (ACSS-FAD) is a seven-item self-report measure which uses a 5-point Likert scale ranging from 0 (not at all like me) to 4 (very much like me).
Scores range from 0 to 32, and higher scores represent a worse outcome (higher levels of the acquired capability for suicide).
|
2 weeks
|
Reflective Functioning Questionnaire
Time Frame: 2 weeks
|
The 8-item version of the Reflective Functioning Questionnaire is a self-reported instrument that measures reflective functioning, an expression of mentalizing processes.
The instrument separately addresses the levels of both certainty and uncertainty about one's own mental processes.
Items are scored in a 7 point-scale (1 to 7), meaning that the total score ranges from 8 to 56, higher scores represent a higher capacity of mentalizing, and therefore a better outcome.
|
2 weeks
|
Columbia Suicide Rating Scale
Time Frame: 1 month
|
The Columbia Suicide Rating Scale is a suicidal ideation and behavior rating scale that evaluates suicide risk.It rates an individual's degree of suicidal ideation on a scale, ranging from "wish to be dead" to "active suicidal ideation with specific plan and intent and behaviors.
It contains 6 "yes" or "no" questions in which respondents are asked to indicate whether they have experienced several thoughts or feelings relating to suicide over the past month and behaviors over their lifetime and past 3 months.
An answer of "yes" to any of the six questions may indicate a need for referral and an answer of "yes" to questions 4, 5 or 6 indicate high-risk.
|
1 month
|
The International Neuropsychiatric Interview (MINI)
Time Frame: Varies on the diagnosis
|
Clinician-rated scale to screen for mental disorders.
The MINI KIDs will be used for participants between 12-17 years of age.
|
Varies on the diagnosis
|
Strengths and Difficulties Questionnaire (SDQ)
Time Frame: 1 month
|
Emotional and behavioral screening questionnaire designed for youths.
|
1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Víctor Pérez, PhD, Parc de Salut Mar
Publications and helpful links
General Publications
- Witt KG, Hetrick SE, Rajaram G, Hazell P, Taylor Salisbury TL, Townsend E, Hawton K. Psychosocial interventions for self-harm in adults. Cochrane Database Syst Rev. 2021 Apr 22;4(4):CD013668. doi: 10.1002/14651858.CD013668.pub2.
- Perez V, Elices M, Toll A, Bobes J, Lopez-Sola C, Diaz-Marsa M, Grande I, Lopez-Pena P, Rodriguez-Vega B, Ruiz-Veguilla M, de la Torre-Luque A; SURVIVE Group. The Suicide Prevention and Intervention Study (SURVIVE): Study protocol for a multisite cohort study with nested randomized-controlled trials. Rev Psiquiatr Salud Ment (Engl Ed). 2020 Dec 7:S1888-9891(20)30127-0. doi: 10.1016/j.rpsm.2020.11.004. Online ahead of print. English, Spanish.
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019/8629/I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
Clinical Trials on Treatment as Usual
-
Universitätsklinikum Hamburg-EppendorfCompletedPerioperative AnxietyGermany
-
South London and Maudsley NHS Foundation TrustCompletedAttention Deficit Hyperactivity DisorderUnited Kingdom
-
McMaster UniversityNot yet recruiting
-
Gaia AGRecruitingType 2 DiabetesGermany
-
Centre for Addiction and Mental HealthCompleted
-
King's College LondonUnknown
-
University Hospital, AkershusUniversity of OsloActive, not recruiting
-
University of IndianapolisUniversity of Missouri, Kansas City; Missouri State UniversityCompletedHypertension | Diabete Type 2United States
-
Universitat Jaume IConsorcio Hospitalario Provincial de CastellónCompletedDepression | AnxietySpain
-
Kuopio University HospitalUniversity of Oslo; University of Eastern Finland; City of KuopioRecruiting